(Pro)renin Receptor Is a Novel Independent Prognostic Marker in Invasive Urothelial Carcinoma of the Bladder.
(pro)renin receptor
biomarker
prognosis
urothelial carcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Nov 2021
11 Nov 2021
Historique:
received:
30
09
2021
revised:
05
11
2021
accepted:
08
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
(Pro)renin receptor (PRR) is being investigated in several malignancies as it activates pathogenic pathways that contribute to cell proliferation, immunosuppressive microenvironments, and acquisition of aggressive neoplastic phenotypes. Its implication in urothelial cancer (UC) has not been evaluated so far. We retrospectively evaluate the prognostic role of PRR expression in a series of patients with invasive UC treated with radical cystectomy and other clinical and histopathological parameters including p53, markers of immune-checkpoint inhibition, and basal and luminal phenotypes evaluated by tissue microarray. Cox regression analyses using stepwise selection evaluated candidate prognostic factors and disease-specific survival. PRR was expressed in 77.3% of the primary tumors and in 70% of positive lymph nodes. PRR expression correlated with age (
Identifiants
pubmed: 34830803
pii: cancers13225642
doi: 10.3390/cancers13225642
pmc: PMC8616163
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundación para la Investigación en Urología, Asociación Española de Urología
ID : FIU-EAU 2017
Organisme : Fundación para la Investigación en Urología, Asociación Española de Urología
ID : FIU-EAU 2019
Organisme : Ministerio de Economía y Competitividad
ID : SAF2016-79847R
Organisme : Instituto de Salud Carlos III
ID : CP20/00008
Références
J Clin Invest. 2002 Jun;109(11):1417-27
pubmed: 12045255
Physiol Rev. 2016 Jul;96(3):1071-91
pubmed: 27335445
Sci Transl Med. 2017 Oct 4;9(410):
pubmed: 28978752
Nat Rev Nephrol. 2019 Nov;15(11):693-712
pubmed: 31164719
J Renin Angiotensin Aldosterone Syst. 2015 Jun;16(2):227-33
pubmed: 23934336
Sci Rep. 2015 Mar 09;5:8854
pubmed: 25747895
Biochim Biophys Acta. 2014 Nov;1842(11):2073-86
pubmed: 25020236
Oncotarget. 2019 Aug 13;10(48):4923-4936
pubmed: 31452834
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Cancer Res Clin Oncol. 1993;119(10):578-93
pubmed: 8335677
Lancet Oncol. 2017 Mar;18(3):271-273
pubmed: 28271858
Cell Commun Signal. 2020 Mar 6;18(1):39
pubmed: 32143717
PLoS One. 2019 Aug 30;14(8):e0221785
pubmed: 31469885
Eur Urol. 2019 Mar;75(3):423-432
pubmed: 30213523
Semin Oncol. 2012 Oct;39(5):524-33
pubmed: 23040249
Tohoku J Exp Med. 2017;241(1):35-43
pubmed: 28090037
World J Nephrol. 2019 Sep 26;8(5):83-94
pubmed: 31624709
PLoS One. 2021 Sep 15;16(9):e0257195
pubmed: 34525114
Biomed Res Int. 2014;2014:768758
pubmed: 24971349
Int J Biol Sci. 2019 Aug 8;15(10):2139-2155
pubmed: 31592144
Biomed Res. 2014;35(2):117-26
pubmed: 24759179
Mol Cancer Res. 2020 Oct;18(10):1477-1490
pubmed: 32587106
Clin Cancer Res. 2017 Oct 1;23(19):5959-5969
pubmed: 28600474
Future Sci OA. 2015 Nov 01;1(3):FSO15
pubmed: 28031890
BMC Res Notes. 2018 Mar 27;11(1):207
pubmed: 29587848
PLoS One. 2017 Aug 15;12(8):e0181711
pubmed: 28809959
Mol Cancer Ther. 2020 Sep;19(9):1844-1855
pubmed: 32669314
Science. 2010 Jan 22;327(5964):459-63
pubmed: 20093472
Cancers (Basel). 2019 Jun 24;11(6):
pubmed: 31238566
Curr Urol Rep. 2019 Jan 15;20(1):1
pubmed: 30645700
Cancer Causes Control. 2015 Sep;26(9):1245-55
pubmed: 26081426
PLoS One. 2013;8(3):e57674
pubmed: 23469216
Diagnostics (Basel). 2021 Feb 10;11(2):
pubmed: 33578778
Eur Urol. 2015 Aug;68(2):238-53
pubmed: 25709027
Oncotarget. 2016 Jul 13;7(34):55437-55448
pubmed: 28874965
Lancet Oncol. 2005 Sep;6(9):678-86
pubmed: 16129368
Hum Pathol. 2019 Sep;91:61-68
pubmed: 31279874
Nat Rev Cancer. 2015 Jan;15(1):25-41
pubmed: 25533674
World J Urol. 2019 Jan;37(1):31-40
pubmed: 30259123